- Home
- BSX vs STAK Comparison
BSX vs STAK Comparison
Compare BSX & STAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSX
- STAK
- Stock Information
- Founded
- BSX 1979
- STAK 2020
- Country
- BSX United States
- STAK China
- Employees
- BSX N/A
- STAK N/A
- Industry
- BSX Medical/Dental Instruments
- STAK
- Sector
- BSX Health Care
- STAK
- Exchange
- BSX Nasdaq
- STAK NYSE
- Market Cap
- BSX 138.5B
- STAK N/A
- IPO Year
- BSX 1992
- STAK 2025
- Fundamental
- Price
- BSX $95.12
- STAK $1.74
- Analyst Decision
- BSX Strong Buy
- STAK
- Analyst Count
- BSX 23
- STAK 0
- Target Price
- BSX $107.61
- STAK N/A
- AVG Volume (30 Days)
- BSX 10.1M
- STAK 1.9M
- Earning Date
- BSX 04-23-2025
- STAK 01-01-0001
- Dividend Yield
- BSX N/A
- STAK N/A
- EPS Growth
- BSX 16.82
- STAK N/A
- EPS
- BSX 1.25
- STAK 0.24
- Revenue
- BSX $16,747,000,000.00
- STAK $18,918,847.00
- Revenue This Year
- BSX $15.60
- STAK N/A
- Revenue Next Year
- BSX $10.28
- STAK N/A
- P/E Ratio
- BSX $76.10
- STAK $7.13
- Revenue Growth
- BSX 17.61
- STAK N/A
- 52 Week Low
- BSX $66.80
- STAK $1.13
- 52 Week High
- BSX $107.17
- STAK $4.53
- Technical
- Relative Strength Index (RSI)
- BSX 45.80
- STAK N/A
- Support Level
- BSX $86.77
- STAK N/A
- Resistance Level
- BSX $96.69
- STAK N/A
- Average True Range (ATR)
- BSX 4.05
- STAK 0.00
- MACD
- BSX -0.02
- STAK 0.00
- Stochastic Oscillator
- BSX 59.74
- STAK 0.00
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.